Virtual Lecture
Individualizing Therapy for Chronic Lymphocytic Leukemia: New Options
Release Date: January 12, 2021
Expiration Date: January 11, 2022
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
program overview
Program Description
With the approval of novel targeted drugs and combination therapies, the complexity of treatment for chronic lymphocytic leukemia (CLL) has increased substantially in recent years. Among the classes of novel oral drugs approved by the FDA are the Bruton’s tyrosine kinase (BTK) inhibitors ibrutinib and acalabrutinib, the phosphatidylinositol-3-kinase (PI3K) inhibitors idelalisib and duvelisib, and the B-cell lymphoma (BCL)-2 inhibitor venetoclax. Combinations of targeted agents have also been approved. These developments, coupled with the identification of molecular prognostic markers and the introduction of more sensitive and sophisticated techniques to assess minimal residual disease (MRD), signal a greater shift toward individualized therapy for patients with CLL. In this activity, an expert from Columbia University Medical Center reviews clinical data and national guidelines for individualizing treatment of patients with newly diagnosed or relapsed/refractory CLL, and discusses strategies to manage adverse events and improve treatment compliance.
Format
Virtual Lecture
Learning Objectives
After completing this activity, participants should be better able to:
- Identify clinical and molecular markers and their potential impact on prognosis and treatment of CLL
- Formulate strategies for treatment of patients with CLL based on clinical evidence and patient and disease factors
- Implement management strategies to address treatment adverse events and patient adherence
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Nicole Lamanna, MD
- Associate Professor of Medicine
- Director, CLL Program
- Columbia University Medical Center
- New York, New York
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Natasha Johnson, APRN, Moffitt Cancer Center, Tampa, Florida
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 11, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Lamanna: consultant/research support: AbbVie AstraZeneca, BeiGene, Genentech, Juno Therapeutics, Octapharma; consultant: Celgene, Janssen, Pharmacyclics; research support: Loxo Oncology, Ming Therapeutics, Oncternal Therapeutics, TG Therapeutics.
Ms Williams speakers bureau: AstraZeneca.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose, except Ms Williams as noted above.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: January 12, 2021
Expiration date: January 11, 2022
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 99520JS